- Home
- ACIU vs BARK Comparison
ACIU vs BARK Comparison
Compare ACIU & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- BARK
- Stock Information
- Founded
- ACIU 2003
- BARK 2011
- Country
- ACIU Switzerland
- BARK United States
- Employees
- ACIU N/A
- BARK N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- BARK Department/Specialty Retail Stores
- Sector
- ACIU Health Care
- BARK Consumer Discretionary
- Exchange
- ACIU Nasdaq
- BARK Nasdaq
- Market Cap
- ACIU 332.4M
- BARK 308.9M
- IPO Year
- ACIU 2016
- BARK N/A
- Fundamental
- Price
- ACIU $2.67
- BARK $1.89
- Analyst Decision
- ACIU Strong Buy
- BARK Buy
- Analyst Count
- ACIU 2
- BARK 2
- Target Price
- ACIU $12.00
- BARK $2.20
- AVG Volume (30 Days)
- ACIU 132.5K
- BARK 1.3M
- Earning Date
- ACIU 11-05-2024
- BARK 02-05-2025
- Dividend Yield
- ACIU N/A
- BARK N/A
- EPS Growth
- ACIU N/A
- BARK N/A
- EPS
- ACIU N/A
- BARK N/A
- Revenue
- ACIU $48,505,404.00
- BARK $488,881,000.00
- Revenue This Year
- ACIU $85.33
- BARK $3.23
- Revenue Next Year
- ACIU $80.69
- BARK $10.01
- P/E Ratio
- ACIU N/A
- BARK N/A
- Revenue Growth
- ACIU 4097200.00
- BARK N/A
- 52 Week Low
- ACIU $2.25
- BARK $0.74
- 52 Week High
- ACIU $5.14
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- ACIU 27.22
- BARK 44.33
- Support Level
- ACIU $2.63
- BARK $1.84
- Resistance Level
- ACIU $3.07
- BARK $2.26
- Average True Range (ATR)
- ACIU 0.15
- BARK 0.13
- MACD
- ACIU -0.04
- BARK -0.06
- Stochastic Oscillator
- ACIU 8.96
- BARK 6.29
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.